Table 1.
Patient | Age | Primary Tumor (before AJ therapy)
|
Adjuvant HTE | Time to recurrence (Month) | Recurrent Tumor (After AI therapy)
|
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
pTNMA | ERB | PRC | HER2D | Site | ER | PR | HER2 | ||||
#1 | 50 | pT4cN1M0 | + | − | 2 | LetF | 30 | Supraclavicular LNI | + | + | 0 |
#2 | 67 | pT2N1M0 | + | + | 3 | AnaG | 18 | Intra-pectoral LN | + | + | 1 |
#3 | 72 | pT1N0M0 | + | − | 2 | ExeH | 43 | Subcutaneous nodule | + | − | 0 |
#4 | 69 | pT1N0M0 | + | − | 3 | Ana | 58 | Subcutaneous nodule | + | + | 3 |
#5 | 60 | pT2N1M0 | + | − | 1 | Ana | 27 | Subcutaneous nodule | + | − | 2 |
#6 | 52 | pT2N1M0 | + | + | 0 | Ana | 33 | Subclavicular LN | + | + | 0 |
#7 | 59 | pT4bN1M0 | + | + | 1 | Ana | 53 | Supraclavicular LN | − | − | 1 |
#8 | 78 | pT1N1M0 | + | + | 1 | Ana | 72 | Supraclavicular LN | + | + | 2 |
#9 | 53 | pT2N0M0 | + | + | 0 | Exe | 72 | Subclavicular LN | + | + | 0 |
#10 | 53 | pT2N1M0 | + | + | 1 | Exe | 68 | Subcutaneous nodule | + | + | 1 |
#11 | 78 | pT3N1M0 | + | − | 0 | Exe | 24 | Subcutaneous nodule | + | − | 0 |
#12 | 53 | pT2N2M0 | + | + | 0 | Ana | 41 | Ipslateral breast | + | +/− | 1 |
pTNM: pathological tumor-lymph nodes-metastasis classification according to the Union Internationale Contra le Cancer (UICC).
ER: Estrogen receptor status.
PR: Progesterone receptor status.
HER2/neu status: HER2.
HT: Hormone therapy.
Let: Letrozole.
Ana: Anastrozole.
Exe: Exemestane.
LN: Lymph nodes.